



MISSION-AD

Alzheimer's Disease Study

Aim

To evaluate the safety and tolerability of the beta secretase inhibitor (E2609) in subjects with early Alzheimer's disease (EAD).

Hypothesis

This a beta secretase inhibitor reduces the formation of potentially neurotoxic A β species, and minimises the associated cognitive and behavioral decline, thereby having a potential for ameliorating the progression of EAD.

The Study

An international placebo-controlled, double-blind, parallel-group, 24-month study to evaluate the efficacy and safety of E2609 in patients with EAD.

Clinical Trial No. NCT03036280

Funding

- Eisai
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the study participants must:

- be 50-85 years of age;
- have a Mini Mental State Exam score ≥ 24 , and
- have a reliable and willing caregiver.

Ethics approval

Bellberry Human Research Ethics Committee
2017-03-249.

Status

Enrolments to commence in mid-2017.

Principal Investigator

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005
Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au